Monitor pipeline progress and future R&D leadership appointments. The consulting arrangement suggests a managed transition, but the departure of a key officer warrants attention to potential delays in clinical development programs.
Price Chart
Executive Summary
Crinetics Pharmaceuticals announced the departure of Jeff Knight as Chief Development and Operating Officer, effective April 10, 2026. He will transition to a one-year consulting role at $400 per hour, capped at 20 hours per month. His unvested equity will be forfeited, and vested options will remain exercisable for three months post-consulting period.
Key Facts
- Jeff Knight stepped down as Chief Development and Operating Officer effective April 10, 2026.
- He will serve as an independent consultant for one year at $400 per hour, up to 20 hours per month.
- Unvested restricted stock units and stock options were forfeited; vested options remain exercisable for three months after the consulting period ends.
- The company entered into a general release agreement with Knight as part of the separation.
Financial Impact
Minimal direct financial impact. Consulting fees capped at $96,000 annually (20 hours/month x $400/hour x 12 months). Loss of key R&D leadership may affect pipeline execution.
Risk Factors
- Potential disruption to R&D strategy and clinical development timelines
- Loss of institutional knowledge in clinical development
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001658247-26-000022 |
| Document: crnx-20260410.htm | 0001658247-26-000022 |
| Document: 0001658247-26-000022-index-headers.html | 0001658247-26-000022 |
| Document: 0001658247-26-000022-index.html | 0001658247-26-000022 |
| Document: 0001658247-26-000022.txt | 0001658247-26-000022 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 11, 2026 21d ago | 15-12G | — | awaiting T+1 | — | — |
Sep 1, 2026 4w ago | 25-NSE | $84.95 $84.95 | · 0.00% | ▼ −0.44% | — |
Sep 1, 2026 4w ago | 8-K | $84.95 $84.95 | · 0.00% | ▼ −0.44% | — |
Aug 14, 2026 7w ago | 8-K | $84.70 $84.75 | ▲ +0.06% | ▲ +0.53% | — |
Aug 3, 2026 8w ago | Press Release | $83.86 $84.00 | ▲ +0.17% | ▲ +0.37% | — |
Jul 10, 2026 12w ago | DEFA14A | $83.67 $83.71 | ▲ +0.05% | ▼ −0.31% | — |
Jul 10, 2026 12w ago | 8-K | $83.67 $83.71 | ▲ +0.05% | ▼ −0.31% | — |
Jun 30, 2026 13w ago | Press Release | $38.68 $42.23 | ▲ +9.18% | ▲ +9.31% | — |
Jun 14, 2026 15w ago | Press Release | $35.12 $35.00 | ▼ −0.34% | ▲ +0.25% | — |
Jun 14, 2026 15w ago | Press Release | $35.12 $35.00 | ▼ −0.34% | ▲ +0.25% | — |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access